Bérénice Hansen

Dr. Bérénice Hansen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Clinical Nutrition
Verified
Journal Article
Open access
BHBérénice Hansen
Bérénice Hansen
MSMarta Sánchez-Castro
Marta Sánchez-Castro
LSLynn Schintgen
Lynn Schintgen
AKArefeh Khakdan
Arefeh Khakdan
JSJochen G. Schneider
Jochen G. Schneider
PWPaul Wilmes
Paul Wilmes
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease affecting approximately 1 % of the global population. It is characterized by swollen and painful joints eventually evolving into bone erosion, cartilage degradation and systemic inflammation, that significantly reduce patients' quality of life. While modern pharmacological treatments often lead to symptom improvement, they are also accompanied by substantial side effects, which can further impair patient wellbeing. Dietary interventions, particularly fasting and caloric restriction (CR), have gained increasing attention as adjunctive strategies for RA prevention and treatment. Their anti-inflammatory potential and ability to modulate the gut microbiome render them an attractive option to accompany or modify medical treatment. However, high-quality research on fasting and CR interventions in humans with RA remains limited, and the underlying mechanisms are not yet fully understood. The present narrative review reflects our current knowledge regarding fasting and CR, emphasising their impact on clinical outcomes, potential underlying mechanism and the sustainability of their effects. Evidence suggests that fasting and CR may lead to short-term improvements in RA disease activity, including reductions in inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6). However, their long-term efficacy remains uncertain due to the limited duration of most studies. Future research should focus on identifying optimal fasting and CR protocols and their feasibility in long-term disease management, along with investigating patient adherence and potential risks associated with fasting interventions.

10 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
BHBérénice Hansen
Bérénice Hansen
EAEvdokia A Alvanou
Evdokia A Alvanou
MPMaria Angeliki Pavlou
Maria Angeliki Pavlou
PWPaul Wilmes
Paul Wilmes
JSJochen G. Schneider
Jochen G. Schneider
Rheumatoid arthritis (RA) is a systemic and chronic autoimmune disease affecting about 1% of the global population, with a higher prevalence in women. Its treatment has been improved greatly over the past 30 years but there is no definitive cure available, and another unmet need exists for transitional hormonal stages such as pregnancy or menopause, which spurs the need to research new therapy options. In recent years, dietary interventions, particularly fasting and plant-based nutrition, have gained attention for their potential to alleviate RA symptoms. Fasting has been shown to reduce systemic inflammation, promote autophagy, and modulate immune cell activity, possibly leading to decreased joint pain and swelling. Nutritional strategies, such as anti-inflammatory and plant-based diets, have been shown to impact the gut microbiome and potentially support weight management, improve metabolic health, and reduce oxidative stress, all of which might contribute to better RA disease outcomes. Although the precise mechanisms remain under investigation, these approaches offer promising complementary strategies for enhancing RA management and improving patients’ quality of life. This review explores the preventive and therapeutic potential of fasting and nutrition in RA, and their possible application in the context of hormonal fluctuations and transitional stages during a women’s life.

24 March 2026 in View
Verified
Journal Article
Open access
CRCharlotte De Rudder
Charlotte De Rudder
KGKacy Greenhalgh
Kacy Greenhalgh
JBJoanna Baginska
Joanna Baginska
CMCamille Martin‐Gallausiaux
Camille Martin‐Gallausiaux
LGLéa Grandmougin
Léa Grandmougin
PWPaul Wilmes
Paul Wilmes
An individual's immune status is an essential factor affecting the efficacy of microbiome‐based therapies. To enable representative studies of microbiome–immune system interactions, we developed protocols to facilitate the coculture of intestinal epithelial cells and human peripheral blood mononuclear cells (PBMCs) in our microphysiological model of the human gut, HuMiX. Using the resulting immunoHuMiX model, we assessed responses to human–microbial cocultures with a probiotic mixture comprised of 17 strictly anaerobic Clostridial strains (17‐mix). We demonstrated the ability of our model to sustain metabolically active microbiota, while maintaining human cell viability, and generated relevant read‐outs for host–microbiome interaction studies. The composition of the strain mixture was not affected by the individual sources of PBMCs, and the abundances of the different immune cell populations were comparable when incubated with or without the 17‐mix after 24 h in the system, and between individuals. We observed increased cytokine production, PBMC viability, and PBMC cell counts upon coculture with the 17‐mix, thereby demonstrating immune sensing of the microbiota by the PBMCs. In summary, our immunoHuMiX model provides an important personalizable tool for screening microbiota‐driven immune responses.

1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
BHBérénice Hansen
Bérénice Hansen
RCRaul Da Costa
Raul Da Costa
DRDominique Revets
Dominique Revets
FHFanny Hedin
Fanny Hedin
MKMaria Konstantinou
Maria Konstantinou
JSJochen G. Schneider
Jochen G. Schneider
Objectives: Over the past decades, the prevalence of noncommunicable diseases has surged significantly, including the systemic autoimmune disorder rheumatoid arthritis (RA). Despite extensive research and advancement of RA therapy, effective prevention strategies or cures remain elusive, and the mechanisms underlying RA pathogenesis unclear. It is crucial to gain deeper insights into RA pathophysiology. The objective of this study is to provide a comprehensive immunophenotyping of patients with RA. Methods: We generated and analyzed deep immunophenotyping data from 52 patients with RA and 47 healthy controls (HCs). Whole blood samples were stained with extracellular markers, and intracellular antibodies and analyzed for 32 different cell markers using mass cytometry by time of flight. The acquired data was analyzed by both manual and automatic unsupervised tools and subsequently complemented with anthropometric data and clinical‐laboratory parameters. Results: We observed a significant disparity in immune cell profiles between patients with RA and HC, notably a reduced frequency of CD27 + IgD + unswitched memory B ( m B) cells in patients with RA ( p ‐value < 0.01), with the disease RA being the primary and only significant factor explaining up to 17.9% of the variance of these cells. Conclusion: Our results reveal, for the first time, that a reduced frequency of unswitched m B cells in patients with RA is the only significant abnormality distinguishing patients with RA from HC in a complex immunophenotyping panel of 72 different cell populations. This provides important information to further individualize various interventions and possibly help to design novel therapeutic interventions.